40372-06-3Relevant articles and documents
Development of a nanostabilized biocatalyst using an extremophilic microorganism for ribavirin biosynthesis
De Benedetti, Eliana C.,Rivero, Cintia W.,Trelles, Jorge A.
, p. 90 - 95 (2015/09/07)
Ribavirin is a guanosine analogue commonly used as an antiviral compound for the treatment of Hepatitis C virus (HCV) infection. The biosynthesis of this compound using Geobacillus kaustophilus ATCC 8005 as biocatalyst is herein reported. This extremophilic microorganism has been successfully entrapped in an agarose matrix supplemented with bentonite, which was defined as bionanocomposite. This immobilized biocatalyst was stable for more than 580 h without activity loss, significantly improving operational stability and mechanical properties over the conventional agarose matrix. Furthermore, a packed-bed bioreactor for bioprocess scale-up was designed, which was able to produce 370 mg L-1 of ribavirin. In conclusion, a smooth, inexpensive and environmentally friendly method to obtain ribavirin was developed in this study.
In search of new inhibitors of HIV-1 replication: Synthesis and study of 1-(2′-deoxy-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide as a selective viral mutagenic agent
Vivet-Boudou,Paillart,Burger,Marquet
, p. 743 - 746 (2008/09/17)
With the emergence of HIV strains resistant or cross-resistant to nearly all antiretroviral regimen, novel therapy approaches have to be considered. As a part of our current work on viral mutagenic compounds, we prepared 1-(2′-deoxy-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (2′-deoxy-ribavirin) and its 5′-triphosphate derivative. The nucleoside mutagenic activity was evaluated on HIV-1 NL4-3 in CEMx174 cell culture. After 2.5 months, no reduction on HIV-1 viability was observed. On the other hand, in vitro experiments with purified HIV-1 RT demonstrated that the triphosphate analog can be incorporated opposite to several natural nucleosides. Copyright Taylor & Francis Group, LLC.